QuidelOrtho (NASDAQ:QDEL) Trading Down 7.5% – Time to Sell?

QuidelOrtho Corporation (NASDAQ:QDEL) shares fell 7.5% during trading on Monday . The company traded as low as $12.63 and last traded at $12.6450. Approximately 499,750 shares changed hands during trading, a decline of 73% from the average daily volume of 1,825,782 shares. The stock had previously closed at $13.67.

Wall Street Analysts Forecast Growth

QDEL has been the topic of a number of recent research reports. Wall Street Zen downgraded QuidelOrtho from a “hold” rating to a “sell” rating in a report on Saturday. Jefferies Financial Group cut QuidelOrtho from a “buy” rating to a “hold” rating and dropped their target price for the stock from $35.00 to $12.50 in a report on Thursday, May 7th. UBS Group restated a “neutral” rating and set a $12.00 target price on shares of QuidelOrtho in a research report on Thursday, May 7th. Citigroup decreased their price target on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 6th. Finally, Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Four investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $14.88.

QuidelOrtho Stock Down 9.5%

The stock has a market capitalization of $843.85 million, a P/E ratio of -0.69 and a beta of 0.77. The company has a current ratio of 1.43, a quick ratio of 0.80 and a debt-to-equity ratio of 1.33. The firm’s fifty day moving average is $12.80 and its 200-day moving average is $20.77.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). The firm had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. QuidelOrtho had a positive return on equity of 4.25% and a negative net margin of 45.57%.QuidelOrtho’s quarterly revenue was down 10.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.74 earnings per share. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. As a group, equities research analysts predict that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Institutional Investors Weigh In On QuidelOrtho

A number of large investors have recently bought and sold shares of the business. Hantz Financial Services Inc. raised its position in shares of QuidelOrtho by 50.3% during the fourth quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after acquiring an additional 362 shares during the last quarter. ProShare Advisors LLC boosted its holdings in QuidelOrtho by 3.0% in the fourth quarter. ProShare Advisors LLC now owns 13,164 shares of the company’s stock valued at $376,000 after acquiring an additional 388 shares during the last quarter. State of Alaska Department of Revenue increased its position in QuidelOrtho by 1.1% in the fourth quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock worth $1,093,000 after purchasing an additional 424 shares during the period. Moody National Bank Trust Division increased its position in QuidelOrtho by 1.0% in the fourth quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock worth $1,471,000 after purchasing an additional 526 shares during the period. Finally, California State Teachers Retirement System raised its holdings in QuidelOrtho by 1.2% during the 2nd quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock worth $1,792,000 after purchasing an additional 725 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.